CYP3A4 and tuberculosis: Co-infection with talaromycosis and tuberculosis is common, with microbiology-confirmed tuberculosis coinfection seen in 22% of patients [3], and presents a therapeutic challenge in that rifampicin as a potent CYP3A4 inducer reduces itraconazole concentration by 60% [18].